R
Rémy Burcelin
Researcher at French Institute of Health and Medical Research
Publications - 208
Citations - 33061
Rémy Burcelin is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Insulin & Insulin resistance. The author has an hindex of 73, co-authored 203 publications receiving 28240 citations. Previous affiliations of Rémy Burcelin include University of Lausanne & Institut national de la recherche agronomique.
Papers
More filters
Journal ArticleDOI
Fatty taste variability in obese subjects: the oral microbiota hypothesis
Philippe Besnard,Jeffrey E. Christensen,Arnaud Bernard,Xavier Collet,Bruno Vergès,Rémy Burcelin +5 more
TL;DR: To check the association between the microbial microenvironment surrounding CVPs and the fatty taste sensitivity, the oro-sensory perception thresholds of linoleic acid and the composition of oral microbiota surrounding the gustatory circumvallate papillae were analyzed in obese adult men.
Journal ArticleDOI
Intestinal RORrt-generated Th17 cells control type 2 diabetes: A first antidiabetic target identified from the host to microbiota crosstalk
TL;DR: An impaired intestinal immune defense, notably the reduced differentiation of RORgt expressing IL17-producing CD4 T cells, favors the onset of a leaky gut leading to the translocation of bacterial factors and live bacteria towards tissues triggering metabolic inflammation; insulin resistance and type 2 diabetes.
Journal ArticleDOI
Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
François Briand,Julie Maupoint,Emmanuel Brousseau,Natalia Breyner,Mélanie Bouchet,Clément Costard,Thierry Leste-Lasserre,Mathieu Petitjean,Li Chen,Audrey Chabrat,Virgile Richard,Rémy Burcelin,Caroline Dubroca,Thierry Sulpice +13 more
TL;DR: In this article, the effects of dual peroxisome proliferator activated receptor alpha/delta agonist elafibranor developed for the treatment of NASH patients were evaluated.
Journal ArticleDOI
Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice
Julie Charpentier,Aurélie Waget,Aurélie Waget,Pascale Klopp,Pascale Klopp,Christophe Magnan,Céline Cruciani-Guglielmacci,Shin J. Lee,Rémy Burcelin,Rémy Burcelin,Estelle Grasset,Estelle Grasset +11 more
TL;DR: It is demonstrated that lixisenatide activates the vagus nerve and recruits the gut-brain axis through the GLP-1 receptor to decrease gastric emptying and stimulate insulin secretion to improve glycemia.
Journal ArticleDOI
A 3-week Nonalcoholic Steatohepatitis Mouse Model Shows Elafibranor Benefits on Hepatic Inflammation and Cell Death
François Briand,Christophe Heymes,Lucile Bonada,Thibault Angles,Julie Charpentier,Maxime Branchereau,Emmanuel Brousseau,Marjolaine Quinsat,Nicolas Fazilleau,Rémy Burcelin,Thierry Sulpice +10 more
TL;DR: A rapid mouse model of liver inflammation and the effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist elafibranor showed strong benefits on NASH, including improvement in hepatic inflammation, necroptosis, and apoptosis in the 3‐week NASH mouse.